Details

Autor(en) / Beteiligte

• Morris, Sapna Bamrah
• Schwartz, Noah G
• Patel, Pragna
• Abbo, Lilian
• Beauchamps, Laura
• Balan, Shuba
• Lee, Ellen H
• Paneth-Pollak, Rachel
• Geevarughese, Anita
• Lash, Maura K
• Dorsinville, Marie S
• Ballen, Vennus
• Eiras, Daniel P
• Newton-Cheh, Christopher
• Smith, Emer
• Robinson, Sara
• Stogsdill, Patricia
• Lim, Sarah
• Fox, Sharon E
• Richardson, Gillian
• Hand, Julie
• Oliver, Nora T
• Kofman, Aaron
• Bryant, Bobbi
• Ende, Zachary
• Datta, Deblina
• Belay, Ermias
• Godfred-Cato, Shana

Titel

Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection - United Kingdom and United States, March-August 2020

Ist Teil von

• MMWR. Morbidity and mortality weekly report, 2020-10, Vol.69 (40), p.1450-1456

Ort / Verlag

United States: U.S. Government Printing Office

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• During the course of the coronavirus disease 2019 (COVID-19) pandemic, reports of a new multisystem inflammatory syndrome in children (MIS-C) have been increasing in Europe and the United States (1-3). Clinical features in children have varied but predominantly include shock, cardiac dysfunction, abdominal pain, and elevated inflammatory markers, including C-reactive protein (CRP), ferritin, D-dimer, and interleukin-6 (1). Since June 2020, several case reports have described a similar syndrome in adults; this review describes in detail nine patients reported to CDC, seven from published case reports, and summarizes the findings in 11 patients described in three case series in peer-reviewed journals (4-6). These 27 patients had cardiovascular, gastrointestinal, dermatologic, and neurologic symptoms without severe respiratory illness and concurrently received positive test results for SARS-CoV-2, the virus that causes COVID-19, by polymerase chain reaction (PCR) or antibody assays indicating recent infection. Reports of these patients highlight the recognition of an illness referred to here as multisystem inflammatory syndrome in adults (MIS-A), the heterogeneity of clinical signs and symptoms, and the role for antibody testing in identifying similar cases among adults. Clinicians and health departments should consider MIS-A in adults with compatible signs and symptoms. These patients might not have positive SARS-CoV-2 PCR or antigen test results, and antibody testing might be needed to confirm previous SARS-CoV-2 infection. Because of the temporal association between MIS-A and SARS-CoV-2 infections, interventions that prevent COVID-19 might prevent MIS-A. Further research is needed to understand the pathogenesis and long-term effects of this newly described condition.